EGFR and hepatocellular carcinoma: Other evidence supporting this hypothesis showed the association of the EGFR pathway with cirrhosis, fibrosis, and HCC, and the reversion of the expression of cirrhosis signature genes by the EGFR inhibitor erlotinib [62,63,77,78,79].